A Phase 3 interventional study of LY2963016 and Lantus® in Type 1 Diabetes, sponsored by Eli Lilly and Company. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-29.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 15th largest by enrollment, is one of 2 that started in 2018, is one of 18 in phase 3, and was the 54th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 272 is above the median of 40 across 2,820 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 73 across the 66 interventional studies. Of the 63 that completed or were terminated, 24 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 66 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company: 4 open now, 6 under way, 4 of them phase 3. Of 66 finished, 49 (74%) have results posted.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 16th largest by enrollment of the 72 interventional ones that give a count, is one of 8 that started in 2018, is one of 23 in phase 3, and was the 39th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 1 studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 75 in Diabetes Mellitus, Type 1:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult Chinese participants with Type 1 Diabetes Mellitus (T1DM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 100 units per milliliter (U/mL) LY2963016 administered subcutaneously (SC) once daily (QD) and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
Drug: LY2963016 · Drug: Insulin Lispro
Participants received 100 U/mL Lantus® administered SC QD and 100 U/mL premeal insulin lispro administered SC thrice-daily (TID) within 15 minutes before meals or immediately after the meal.
Drug: Lantus® · Drug: Insulin Lispro
Administered SC
Administered SC
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated using mixed-effects model for repeated measures (MMRM) with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).
Time frame: Baseline, Week 24
Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).
Time frame: Baseline, Week 24
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Before Morning Meal Glucose, 2 Hours After Morning Meal Glucose, Before Mid-Day Meal Glucose, 2 Hours After Mid-Day Meal Glucose, Before Evening Meal Glucose, Bedtime Glucose and 0300 Am Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 24
Percentage of Participants With HbA1c <7%
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
Time frame: Week 24
Percentage of Participants With HbA1c ≤6.5%
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
Time frame: Week 24
Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG
Change From Baseline in Intrapatient blood glucose (BG). LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 24
Change From Baseline in Glycemic Variability of Fasting Blood Glucose
Change From Baseline in Glycemic Variability of Fasting Blood Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
Time frame: Baseline, Week 24
Change From Baseline in Basal Insulin Dose
Change from baseline in basal insulin dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 24
Change From Baseline in Prandial Insulin Dose
Prandial Insulin Dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 24
Change From Baseline in Body Weight
Change from baseline in body weight. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
Time frame: Baseline, Week 24
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ)
The ITSQ is a validated 22-item questionnaire that was used to assess treatment satisfaction. Items were measured on a 7-point scale, with lower scores reflecting better outcomes. In addition to an overall score, scores were also obtained for 5 domains, including inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Raw domain and overall scores were transformed on a scale from 0 to 100, where a higher score indicated better treatment satisfaction. LS mean was calculated using ANCOVA with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment (Type III sum of squares).
Time frame: Baseline, Week 24
Number of Participants With Detectable Anti-Glargine Antibodies
Number of participants with detectable anti-glargine antibodies
Time frame: Baseline through Week 24
Rate of Documented Symptomatic Hypoglycemia
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25) as an offset variable.
Time frame: Baseline through Week 24
| Milestone | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Started | 137 | 135 |
| Received at least one dose of study drug | 137 | 135 |
| Completed | 128 | 125 |
| Not completed | 9 | 10 |
| Withdrew: Withdrawal by subject | 3 | 4 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 1 | 2 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated using mixed-effects model for repeated measures (MMRM) with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).
| Percentage of HbA1c | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®) | -0.20 ± 0.071 | -0.08 ± 0.071 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\*Treatment (Type III sum of squares).
| Percentage of HbA1c | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016) | -0.20 ± 0.071 | -0.08 ± 0.071 |
The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Before Morning Meal Glucose, 2 Hours After Morning Meal Glucose, Before Mid-Day Meal Glucose, 2 Hours After Mid-Day Meal Glucose, Before Evening Meal Glucose, Bedtime Glucose and 0300 Am Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
| milligrams per deciliter (mg/dL) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Before Morning Meal Glucose | -7.2 ± 3.64 | -0.4 ± 3.68 |
| 2 Hours After Morning Meal Glucose | -10.6 ± 4.77 | -2.8 ± 4.83 |
| Before Mid-Day Meal Glucose | -4.6 ± 4.13 | 8.5 ± 4.21 |
| 2 Hours After Mid-Day Meal Glucose | -1.6 ± 4.76 | 1.9 ± 4.76 |
| Before Evening Meal Glucose | -6.2 ± 4.78 | 4.8 ± 4.85 |
| Bedtime Glucose | -0.4 ± 4.99 | 5.0 ± 5.06 |
| 0300 Am Glucose | -4.9 ± 3.87 | 2.5 ± 3.94 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
| percentage of participants | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Percentage of Participants With HbA1c <7% | 30.7 | 32.8 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.
| percentage of participants | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Percentage of Participants With HbA1c ≤6.5% | 15.7 | 22.4 |
Change From Baseline in Intrapatient blood glucose (BG). LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
| mg/dL | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG | -2.9 ± 1.33 | -2.6 ± 1.34 |
Change From Baseline in Glycemic Variability of Fasting Blood Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares).
| mg/dL | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Morning Pre-meal Standard Deviation | -9.0 ± 2.53 | -5.5 ± 2.56 |
| Daily Mean Standard Deviation | -10.4 ± 1.69 | -8.6 ± 1.71 |
Change from baseline in basal insulin dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| Units per Day (U/day) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in Basal Insulin Dose | 0.7 ± 0.33 | 1.5 ± 0.33 |
Prandial Insulin Dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| U/day | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in Prandial Insulin Dose | 0.2 ± 0.49 | 1.4 ± 0.50 |
Change from baseline in body weight. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.
| kilograms (kg) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Change From Baseline in Body Weight | 0.8 ± 0.21 | 0.9 ± 0.22 |
The ITSQ is a validated 22-item questionnaire that was used to assess treatment satisfaction. Items were measured on a 7-point scale, with lower scores reflecting better outcomes. In addition to an overall score, scores were also obtained for 5 domains, including inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Raw domain and overall scores were transformed on a scale from 0 to 100, where a higher score indicated better treatment satisfaction. LS mean was calculated using ANCOVA with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment (Type III sum of squares).
| score on a scale | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| ITSQ Inconvenience of Regimen Transformed Score | 3.5 ± 1.30 | 3.8 ± 1.29 |
| ITSQ Lifestyle Flexibility Transformed Score | 1.3 ± 1.86 | 2.0 ± 1.86 |
| ITSQ Hypoglycemic Control Transformed Score | 3.2 ± 1.39 | 3.8 ± 1.38 |
| ITSQ Glycemic Control Transformed Score | 6.9 ± 1.64 | 6.0 ± 1.64 |
| ITSQ Insulin Delivery Device Satisfaction Transformed Score | 3.3 ± 1.26 | 2.9 ± 1.26 |
| ITSQ Total Transformed Score | 3.3 ± 1.10 | 4.1 ± 1.10 |
Number of participants with detectable anti-glargine antibodies
| Participants | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Detectable Anti-Glargine Antibodies | 76 | 68 |
| Detectable Cross Reactive Insulin Antibodies | 67 | 58 |
| Treatment Emergent Antibody Response (TEAR) | 42 | 35 |
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25) as an offset variable.
| events/participant/year | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Rate of Documented Symptomatic Hypoglycemia | 12.6 ± 2.42 | 14.0 ± 2.64 |
Collected over Baseline Up To 28 Weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 + Insulin Lispro | 0/137 (0%) | 9/137 (6.6%) | 84/137 (61.3%) |
| Lantus® + Insulin Lispro | 0/135 (0%) | 8/135 (5.9%) | 77/135 (57%) |
| Event | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 2/137 | 3/135 |
| PneumoniaInfections and infestations | 0/137 | 2/135 |
| Ovarian disorderReproductive system and breast disorders | 1/77 | 0/66 |
| GastroenteritisInfections and infestations | 1/137 | 1/135 |
| Urinary tract infectionInfections and infestations | 0/137 | 1/135 |
| Spinal fractureInjury, poisoning and procedural complications | 0/137 | 1/135 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/137 | 1/135 |
| NephritisRenal and urinary disorders | 0/137 | 1/135 |
| PerinephritisRenal and urinary disorders | 0/137 | 1/135 |
| UreterolithiasisRenal and urinary disorders | 1/137 | 1/135 |
| Event | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 34/137 | 23/135 |
| NasopharyngitisInfections and infestations | 12/137 | 14/135 |
| Injection site painGeneral disorders | 4/137 | 7/135 |
| DiarrhoeaGastrointestinal disorders | 7/137 | 3/135 |
| ToothacheGastrointestinal disorders | 2/137 | 6/135 |
| Urinary tract infectionInfections and infestations | 5/137 | 2/135 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/137 | 3/135 |
| GastroenteritisInfections and infestations | 0/137 | 4/135 |
| PharyngitisInfections and infestations | 1/137 | 4/135 |
| Weight increasedInvestigations | 4/137 | 4/135 |
All randomized participants.
| Age, Continuous(years) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 41.8 ± 15.0 | 41.4 ± 13.8 | 41.6 ± 14.4 |
| Sex: Female, Male(Participants) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Female | 77 | 66 | 143 |
| Male | 60 | 69 | 129 |
| Ethnicity (NIH/OMB)(Participants) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 137 | 135 | 272 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 137 | 135 | 272 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| China | 137 | 135 | 272 |
| Hemoglobin A1c (HbA1c) at Baseline(Percentage of HbA1c) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 7.90 ± 1.32 | 7.85 ± 1.48 | 7.88 ± 1.40 |
| Duration of Diabetes in years(years) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 10.29 ± 9.53 | 10.53 ± 9.53 | 10.41 ± 9.51 |
| Body Mass Index (BMI)(kilogram per meter square (kg/m²)) | LY2963016 + Insulin Lispro | Lantus® + Insulin Lispro | Total |
|---|---|---|---|
| Mean | 21.90 ± 2.54 | 22.03 ± 2.32 | 21.96 ± 2.43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and asigned data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2018 to primary completion in Mar 2020, 23 months.
Results were first posted in Mar 2021, 1 year after primary completion.
Of 78 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 23 months is above that.
Counting every sponsor, half of 106 studies reached it within 18 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine